NEW YORK, May 13, 2004 (PRIMEZONE) -- The following is an investment opinion issued by Investrend Research Syndicate:
Fundamental Research Corp. has rated the shares of The Jenex Corporation (TSX Venture Exchange:JEN) (Frankfurt/Berlin:JNX) a "Buy -- 5 (Highly Speculative)" and placed a fair value of C$1.00 (current price: $0.28). The following is a summary of the full 17-Page report which is available free at www.fundamentalresearchcorp.com. A May 11, 2004, release incorrectly stated the fees paid for the report. The amount is corrected below.
The company owns the patents to thermal therapy technology devices that use heat to treat certain ailments. The most recent product resulting from this technology, which is in the final stages of development, is the Interceptor(CS)(TM) . The hand-held device will use heat to prevent the symptoms of Herpes Labialis more commonly referred to as cold sores.
The company has approval in Canada to make the claim that the device prevents cold sores, and is expected to begin commercialization in Canada sometime in November, 2004. The company is also seeking approval in Europe, the USA, and Australia. The report estimates that 40-80% of the population has the Herpes Simplex (HSV-1) Virus, and of these, 20-40% experience recurring outbreaks. Using these figures and the device's estimated selling price of C$79.99, it was estimated that the potential market is C$4.9 billion in the U.S., Canada, and EU.
The report cautions that the company is in very early stages of commercialization, and certain milestones must be achieved in order to support the rating and fair value. Specifically, the company must: successfully gain regulatory approval in the USA and EU; secure a manufacturer (expected in 60 days); secure distribution agreements in the markets it intends to serve; and successfully market the product. Other risks include non-acceptance by consumers. Investors are advised to read the complete report including important disclosures, and further risk factors.
Fundamental Research Corp. is an affiliate of Investrend Research and a member of the FIRST Research Consortium which sets the standards and ethics for independent research agreed to by all members of the association.
A fee of $5,000 was paid by the company to issue the research report. A previous release dated May 11, 2004, incorrectly stated that the company paid $25,000.
Complete information about this company is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and the full report is available at: http://www.fundamentalresearchcorp.com/PDF/jenrating.pdf and www.investrendresearch.com , on each report and press release, investors are advised to read disclosures carefully before trading in the equities of any enrolled company.
Anyone interested in receiving alerts regarding The Jenex Corporation research should email info@investrend.com and distribution@fundamentalresearchcorp.com with "JEN" in the subject line.